Home › Funds › Zurcher Kantonalbank (Zurich Cantonalbank) › VRTX

Zurcher Kantonalbank (Zurich Cantonalbank) position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Zurcher Kantonalbank (Zurich Cantonalbank) reported holding 447,079 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$233.7M, representing 0.44% of its reported portfolio and ranking #29 among its reported holdings. Zurcher Kantonalbank (Zurich Cantonalbank) has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)447.08K sh
Reported value held$233.74M
Portfolio Weight0.44%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Zurcher Kantonalbank (Zurich Cantonalbank)'s VRTX position evolved

Zurcher Kantonalbank (Zurich Cantonalbank) first disclosed a stake in VRTX in Q3 2023 at 427,001 shares (US$148.5M). The position peaked in Q3 2026 at 447,079 shares, worth US$233.7M. Across 13 filings, Zurcher Kantonalbank (Zurich Cantonalbank) increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 447,079 shares valued at US$233.7M — an increase of 66,317 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 427.00K $148.49M New
Q4 2023 445.19K $181.14M Add
Q1 2024 434.33K $181.56M Reduce
Q2 2024 388.85K $182.26M Reduce
Q3 2024 320.14K $148.89M Reduce
Q4 2024 349.48K $140.73M Add
Q1 2025 384.71K $186.52M Add
Q2 2025 394.37K $175.57M Add
Q3 2025 388.31K $152.08M Reduce
Q4 2025 353.49K $160.26M Reduce
Q1 2026 377.01K $168.35M Add
Q2 2026 380.76K $189.14M Add
Q3 2026 447.08K $233.74M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Zurcher Kantonalbank (Zurich Cantonalbank) held VRTX?

Zurcher Kantonalbank (Zurich Cantonalbank) has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Zurcher Kantonalbank (Zurich Cantonalbank)'s current position in VRTX?

As of Q3 2026, Zurcher Kantonalbank (Zurich Cantonalbank) holds 447.08K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $233.74M, representing 0.44% of its reported portfolio and ranking #29.

Has Zurcher Kantonalbank (Zurich Cantonalbank) been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Zurcher Kantonalbank (Zurich Cantonalbank) increased its position in VRTX. The position peaked in Q3 2026 at 447.08K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.